XOMA Royalty (NASDAQ:XOMA) Announces Earnings Results, Misses Estimates By $0.02 EPS

XOMA Royalty (NASDAQ:XOMA) posted its quarterly earnings results on Tuesday. The biotechnology company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02), FiscalAI reports. The company had revenue of $12.32 million during the quarter, compared to analyst estimates of $13.91 million. XOMA Royalty had a return on equity of 10.32% and a net margin of 45.75%.

XOMA Royalty Stock Up 0.6%

NASDAQ XOMA traded up $0.25 during trading hours on Tuesday, reaching $41.75. 83,679 shares of the company’s stock traded hands, compared to its average volume of 362,370. XOMA Royalty has a 52-week low of $22.29 and a 52-week high of $42.81. The firm has a market cap of $497.66 million, a PE ratio of 28.60 and a beta of 0.90. The firm has a 50-day simple moving average of $33.63 and a 200 day simple moving average of $30.37. The company has a debt-to-equity ratio of 1.15, a current ratio of 3.37 and a quick ratio of 3.37.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on XOMA shares. Lucid Cap Mkts cut shares of XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. HC Wainwright lowered shares of XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price target on the stock. in a research report on Thursday, April 30th. Zacks Research raised shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. Leerink Partners reaffirmed an “outperform” rating on shares of XOMA Royalty in a research note on Tuesday, February 24th. Finally, TD Cowen raised shares of XOMA Royalty to a “hold” rating in a research note on Friday, February 13th. Two equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, XOMA Royalty presently has a consensus rating of “Hold” and a consensus target price of $53.75.

Institutional Trading of XOMA Royalty

A number of large investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. boosted its holdings in shares of XOMA Royalty by 3,436.4% in the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after buying an additional 756 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of XOMA Royalty by 203.1% in the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,523 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of XOMA Royalty by 13.9% in the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after buying an additional 543 shares in the last quarter. Raymond James Financial Inc. bought a new stake in XOMA Royalty in the second quarter worth $116,000. Finally, BNP Paribas Financial Markets increased its position in XOMA Royalty by 266.6% in the third quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 2,346 shares during the last quarter. 95.92% of the stock is currently owned by institutional investors.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.